MOSCOW, Dec. 12, 2013 /PRNewswire/ -- Rafarma
Pharmaceuticals (OTC:RAFA), announces a $1.2
million private placement.
A $1.2 million private placement
has been closed with a share price of $0.65 per share. Proceeds from this private
placement are being applied to company expansion and to reduce
commercial debt.
Stated CEO Dave Anderson: "As
Rafarma continues to develop new manufacturing partners, we
anticipate that this private placement is just the beginning of a
vibrant private financing market for the pharmaceutical sector. We
are pleased with the investor enthusiasm in Rafarma's
potential."
The securities offered in the private placement have not been
registered under the Securities Act of 1933, as amended (the
"Securities Act"), or applicable state securities laws.
Accordingly, the securities may not be offered or sold in
the United States except pursuant
to an effective registration statement or an applicable exemption
from the registration requirements of the Securities Act and such
applicable state securities laws. The securities were offered only
to accredited investors.
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art
manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces
generic antibiotics and specialty pharmaceuticals in addition to
its own line of proprietary products that are approved by the
Ministry of Health of Russian
Federation. For the last three years, the Russian Government
has been highly focused on bolstering the development of the
nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals'
mission is to work with the auspices of aggressive federal
initiatives to fast-track the modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit:
http://rafarma.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. When used in this press release, the words
"anticipate," "believe," "estimate," "may," "intend," "expect" and
similar expressions identify such forward-looking statements.
Actual results, performance or achievements could differ materially
from those contemplated, expressed or implied by the
forward-looking statements contained herein. These forward-looking
statements are based largely on the expectations of the Company and
are subject to a number of risks and uncertainties. These include,
but are not limited to: the impact of economic, competitive and
other factors affecting the Company and its operations, markets,
product, and distributor performance.
RELATED LINKS
Website: www.Rafarma.com
Facebook: www.facebook.com/Rafarmainfo
Twitter: www.twitter.com/Rafarmainfo
Contact: David Anderson,
info@rafarma.com
SOURCE Rafarma Pharmaceuticals, Inc.
